Curon Medical's low stockholder equity falls foul of US stock market:
This article was originally published in Clinica
Curon Medical, the Fremont, California company focused on treatment of gastrointestinal disorders, is facing possible delisting from the US Nasdaq stock exchange. The firm's stockholder equity, as of the end of 2005, was $2.2m, falling short of the minimum $2.5m stipulated by Nasdaq to remain listed on the exchange. Curon, which has seen its share price trading below $1 for nearly a year, is now required to provide by February 22 a plan for regaining market compliance.